Journal of Literature Pharmacy Sciences

Fajların Antimikrobiyal Tedavide Kullanımı
Applications of Phages in Antimicrobial Therapy
Ece TÜRKMENa, Sevda ŞENELa
aHacettepe Üniversitesi Eczacılık Fakültesi, Farmasötik Teknoloji ABD, Ankara, TÜRKİYE
J Lit Pharm Sci. 2020;9(3):271-84
doi: 10.5336/pharmsci.2020-73682
Article Language: TR
Full Text
ÖZET
 Antimikrobiyal direnç [Antimicrobial resistance (AMR)], artan morbidite, mortalite ve tedavi maliyetleriyle ilişkili ekonomik ve sosyal maliyetler nedeniyle önemli bir halk sağlığı sorunudur. AMR artışı, bakteriyel enfeksiyonlara karşı antibiyotik tedavisinden tarihsel olarak önce gelen bakteriyofaj tedavisine olan ilginin yeniden artmasına neden olmuştur. Bakteriyofajlar, Doğu Avrupa'da çeşitli enfeksiyon hastalıklarının tedavisinde 10'larca yıldır başarıyla kullanılmakta olup, bugüne kadar bakteriyofajların yol açtığı herhangi bir ciddi advers etki bildirilmemiştir. Bakteriyofajlar, DNA ya da RNA içeren, insan veya hayvan hücreleri üzerinde herhangi bir olumsuz etkiye neden olmadan bakterileri enfekte ve lize edebilen virüslerdir. Bakteriyel enfeksiyonların tedavisinde, tek başlarına veya antibiyotiklerle kombine hâlde kullanılmaktadır. Ancak kullanılan fajların uluslararası kabul edilmiş resmî kılavuzlarda belirtilen gerekliliklere uygun kalite, etkinlik ve güvenlilik çalışmalarının tamamlanmaması nedeniyle bazı Doğu Avrupa ülkeleri dışında, rutin klinik uygulamaları henüz onaylı değildir. Bakteriyofaj çözeltilerin stabilitesiyle ilgili karşılaşılan sorunları çözmek amacıyla, fajlar dondurarak kurutma (liyofilizasyon) veya püskürterek kurutma yöntemleriyle toz formlarda hazırlanmış, ayrıca lipozomlar, polimerik mikro ve nanopartiküller gibi farklı taşıyıcı sistemler içine enkapsüle edilmiştir. Bu derlemede, faj tedavisi ve güncel durumu özetlenecek, formülasyon ve standardizasyon yönüyle neler gerektiği tartışılacaktır.

Anahtar Kelimeler: Antimikrobiyal direnç; bakteriyofaj tedavisi; bakteriyel enfeksiyon; formülasyon
ABSTRACT
 Antimicrobial resistance (AMR) is a significant public health concern due to the economic and social costs associated with increased morbidity, mortality, and treatment costs. The rise of AMR has resulted in an increased interest in bacteriophage therapy, which historically preceded antibiotic treatment against bacterial infections. To date, there have been no reports of serious adverse effects caused by bacteriophages, and they have been used successfully for decades to treat human diseases in Eastern Europe. Bacteriophages (phages) are viruses that contain DNA or RNA that can infect and lysate bacteria without causing any adverse effects on human or animal cells. They are used alone or in combination with antibiotics in the treatment of bacterial infections. However due to the lack of quality, efficacy and safety studies based international regulatory guidelines, phages are not officially approved for clinical applications other than some East European countries. Hence, in order to meet the regulatory requirements, studies demonstrating quality and safety of the phages are needed to be completed. To enhance their stability, phages are freeze-dried (lyophilized) or spray dried to get dry forms or they are encapsulated into delivery systems such as polymeric micro or nanoparticles, and liposomes. In this review, the current bacteriophage therapy will be reviewed and the needs in regard to standardization and formulation of bacteriophage therapy will be discussed.

Keywords: Antimicrobial resistance; bacteriophage therapy; bacterial infection; formulation
REFERENCES:
  1. WHO. "No time to wait: securing the future from drug-resistant infections". (Erişim tarihi: 10.9.2019)[Link] 
  2. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. (Erişim tarihi: 10.9.2019)[Link] 
  3. Republic of Turkey ministry of health public health institution. [National antimicrobial resistance surveillance system 2016 annual report]. (Erişim tarihi: 10.9.2019)[Link] 
  4. WHO/Europe. "Central asian and eastern european surveillance of antimicrobial resistance annual report 2018". (Erişim tarihi: 9.9.2019)[Link] 
  5. Principi N, Silvestri E, Esposito S. Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol. 2019;8;10:513.[Crossref] [PubMed] [PMC] 
  6. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Front Microbiol. 2019;1;10:539.[Crossref] [PubMed] [PMC] 
  7. Moelling K, Broecker F, Willy C. A wake-up call: we need phage therapy now. Viruses. 2018;5;10(12):688.[Crossref] [PubMed] [PMC] 
  8. Malik DJ, Sokolov IJ, Vinner GK, Mancuso F, Cinquerrui S, Vladisavljevic GT, et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci. 2017;249:100-33.[Crossref] [PubMed] 
  9. Vandenheuvel D, Lavigne R, Brüssow H. Bacteriophage Therapy: advances in formulation strategies and human clinical trials. Annu Rev Virol. 2015;2(1):599-618.[Crossref] [PubMed] 
  10. Puapermpoonsiri U, Spencer J, van der Walle CF. A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur J Pharm Biopharm. 2009;72(1):26-33.[Crossref] [PubMed] 
  11. Merabishvili M, Vervaet C, Pirnay JP, De Vos D, Verbeken G, Mast J, et al. Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization). PLoS One. 2013;2;8(7):e68797.[Crossref] [PubMed] [PMC] 
  12. Leung SS, Parumasivam T, Gao FG, Carrigy NB, Vehring R, Finlay WH, et al. Production of inhalation phage powders using spray freeze drying and spray drying techniques for treatment of respiratory infections. Pharm Res. 2016;33(6):1486-96.[Crossref] [PubMed] [PMC] 
  13. Ma Y, Pacan JC, Wang Q, Xu Y, Huang X, Korenevsky A, et al. Microencapsulation of bacteriophage felix O1 into chitosan-alginate microspheres for oral delivery. Appl Environ Microbiol. 2008;74(15):4799-805.[Crossref] [PubMed] [PMC] 
  14. Esteban PP, Alves DR, Enright MC, Bean JE, Gaudion A, Jenkins AT, et al. Enhancement of the antimicrobial properties of bacteriophage-K via stabilization using oil-in-water nano-emulsions. Biotechnol Prog. 2014;30(4):932-44.[Crossref] [PubMed] 
  15. Vinner GK, Rezaie-Yazdi Z, Leppänen M, Sta­pley aGF, Leaper MC, Malik Dj, et al. Microencapsulation of salmonella-specific bacteriophage felix O1 using spray-drying in a ph-responsive formulation and direct com­pression tableting of powders into a solid oral dosage form. Pharmaceuticals. 2019;12(43).[Crossref] [PubMed] [PMC] 
  16. Furfaro LL, Payne MS, Chang BJ. Bacteriophage therapy: clinical trials and regulatory hurdles. Front Cell Infect Microbiol. 2018;23;8:376.[Crossref] [PubMed] [PMC] 
  17. Hyman P, Abedon ST. Bacteriophage: Overview. In: Schmidt TM, ed. Encyclopedia of Microbiology. 4th ed. Oxford: Academic Press; 2019. p.441-57.
  18. Domingo-Calap P, Delgado-Martínez J. Bacteriophages: protagonists of a post-antibiotic era. Antibiotics (Basel). 2018;27;7(3):66.[Crossref] [PubMed] [PMC] 
  19. Harada LK, Silva EC, Campos WF, Del Fiol FS, Vila M, Dąbrowska K, et al. Biotechnological applications of bacteriophages: State of the art. Microbiol Res. 2018;212-213:38-58.[Crossref] [PubMed] 
  20. Gündoğdu A, Ulu-Kılıç A. [Bacteriophage therapy: an unforgetten source of cure]. Klimik Derg. 2018;31(2):78-87.[Link] 
  21. Kakasis A, Panitsa G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. Int J Antimicrob Agents. 2019;53(1):16-21.[Crossref] [PubMed] 
  22. Hawkins C, Harper D, Burch D, Anggård E, Soothill J. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet Microbiol. 2010;15;146(3-4):309-13.[Crossref] [PubMed] 
  23. Merabishvili M, Pirnay JP, Vogele K, Malik DJ. Production of phage therapeutics and formulations: innovative approaches. In: Górski A, Międzybrodzki R, Borysowski J, eds. Phage Therapy: A Practical Approach. Cham: Springer International Publishing; 2019. p.3-41.[Crossref] 
  24. Bruttin A, Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother. 2005;49(7):2874-8.[Crossref] [PubMed] [PMC] 
  25. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage. 2011;1(2):66-85.[Crossref] [PubMed] [PMC] 
  26. García P, Martínez B, Obeso JM, Rodríguez A. Bacteriophages and their application in food safety. Lett Appl Microbiol. 2008;47(6):479-85.[Crossref] [PubMed] 
  27. Svircev A, Roach D, Castle A. Framing the Future with bacteriophages in agriculture. Viruses. 2018;25;10(5):218.[Crossref] [PubMed] [PMC] 
  28. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649-59.[Crossref] [PubMed] [PMC] 
  29. Gündoğdu A, Kılıç H, Ulu Kılıç A, Kutateladze M. [Susceptibilities of multidrug-resistant pathogens responsible for complicated skin and soft tissue infections to standard bacteriophage cocktails]. Mikrobiyol Bul. 2016;50(2):215-23.[Crossref] [PubMed] 
  30. Debarbieux L, Pirnay JP, Verbeken G, De Vos D, Merabishvili M, Huys I, et al. A bacteriophage journey at the European Medicines Agency. FEMS Microbiol Lett. 2016;363(2):fnv225.[Crossref] [PubMed] [PMC] 
  31. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1(2):111-4.[Crossref] [PubMed] [PMC] 
  32. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014;1;5(1):226-35.[Crossref] [PubMed] [PMC] 
  33. Jault P, Leclerc T, Jennes S, Pirnay JP, Que YA, Resch G, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19(1):35-45.[Crossref] [PubMed] 
  34. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A, et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009;18(6):237-8.[Crossref] [PubMed] 
  35. Speck P, Smithyman A. Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett. 2016;363(3):fnv242.[Crossref] [PubMed] 
  36. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;22;61(10):e00954-17.[Crossref] [PubMed] [PMC] 
  37. Colom J, Cano-Sarabia M, Otero J, Cortés P, Maspoch D, Llagostera M, et al. Liposome-encapsulated bacteriophages for enhanced oral phage therapy against salmonella spp. Appl Environ Microbiol. 2015;81(14):4841-9.[Crossref] [PubMed] [PMC] 
  38. Sarker SA, Sultana S, Reuteler G, Moine D, Descombes P, Charton F, et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from bangladesh. EBioMedicine. 2016;5;4:124-37.[Crossref] [PubMed] [PMC] 
  39. Markoishvili K, Tsitlanadze G, Katsarava R, Morris JG Jr, Sulakvelidze A. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int J Dermatol. 2002;41(7):453-8.[Crossref] [PubMed] 
  40. Jikia D, Chkhaidze N, Imedashvili E, Mgaloblishvili I, Tsitlanadze G, Katsarava R, et al. The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90. Clin Exp Dermatol. 2005;30(1):23-6.[Crossref] [PubMed] 
  41. Pirnay J-P, Merabishvili M, Van Raemdonck H, De Vos D, Verbeken G. Bacteriophage production in compliance with regulatory requirements. In: Azeredo J, Sillankorva S, eds. Bacteriophage Therapy: From Lab to Clinical Practice. New York, NY: Springer New York; 2018. p.233-52.[Crossref] [PubMed] 
  42. Pirnay JP, Verbeken G, Ceyssens PJ, Huys I, De Vos D, Ameloot C, et al. The magistral phage. Viruses. 2018;6;10(2):64.[Crossref] [PubMed] [PMC] 
  43. Phage therapy unit of the medical centre of the institute of immunology and experimental therapy PAS. (Erişim tarihi: 15.9.2019)[Link] 
  44. Schmidt C. Phage therapy's latest makeover. Nat Biotechnol. 2019;37(6):581-6.[Crossref] [PubMed] 
  45. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349-57.[Crossref] [PubMed] 
  46. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25(5):730-3.[Crossref] [PubMed] [PMC] 
  47. Cooper CJ, Koonjan S, Nilsson AS. Enhancing whole phage therapy and their derived antimicrobial enzymes through complex formulation. Pharmaceuticals (Basel). 2018;19;11(2):34.[Crossref] [PubMed] [PMC] 
  48. McCallin S, Sacher JC, Zheng J, Chan BK. Current State of Compassionate Phage Therapy. Viruses. 2019;11(4):343.[Crossref] [PubMed] [PMC] 
  49. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol. 2011;63(10):1253-64.[Crossref] [PubMed] 
  50. Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother. 2007;51(8):2765-73.[Crossref] [PubMed] [PMC] 
  51. Chadha P, Katare OP, Chhibber S. Liposome loaded phage cocktail: enhanced therapeutic potential in resolving Klebsiella pneumoniae mediated burn wound infections. Burns. 2017;43(7):1532-43.[Crossref] [PubMed] 
  52. Colom J, Cano-Sarabia M, Otero J, Arí-ez-Soriano J, Cortés P, Maspoch D, et al. Microencapsulation with alginate/CaCO3: a strategy for improved phage therapy. Sci Rep. 2017;25;7:41441.[Crossref] [PubMed] [PMC] 
  53. Vinner GK, Vladisavljević GT, Clokie MRJ, Malik DJ. Microencapsulation of Clostridium difficile specific bacteriophages using microfluidic glass capillary devices for colon delivery using pH triggered release. PLoS One. 2017;12;12(10):e0186239.[Crossref] [PubMed] [PMC] 
  54. Abdelsattar AS, Abdelrahman F, Dawoud A, Connerton IF, El-Shibiny A. Encapsulation of E.coli phage ZCEC5 in chitosan-alginate beads as a delivery system in phage therapy. AMB Express. 2019;17;9(1):87.[Crossref] [PubMed] [PMC] 
  55. Łobocka MB, Głowacka A, Golec P. Methods for bacteriophage preservation. In: Azeredo J, Sillankorva S, editors. Bacteriophage therapy: From lab to clinical practice. New York: Springer New York; 2018. p.219-30.[Crossref] [PubMed] 
  56. Brown TL, Petrovski S, Hoyle D, Chan HT, Lock P, Tucci J, et al. Characterization and formulation into solid dosage forms of a novel bacteriophage lytic against Klebsiella oxytoca. PLoS One. 2017;17;12(8):e0183510.[Crossref] [PubMed] [PMC] 
  57. Brown TL, Thomas T, Odgers J, Petrovski S, Spark MJ, Tucci J, et al. Bacteriophage formulated into a range of semisolid and solid dosage forms maintain lytic capacity against isolated cutaneous and opportunistic oral bacteria. J Pharm Pharmacol. 2017;69(3):244-53.[Crossref] [PubMed] 
  58. Bean JE, Alves DR, Laabei M, Esteban PP, Thet NT, Enright MC, et al. Triggered release of bacteriophage K from agarose/hyaluronan hydrogel matrixes by staphylococcus aureus virulence factors. Chem Mater. 2014;26(24):7201-8.[Crossref] 
  59. Hathaway H, Alves DR, Bean J, Esteban PP, Ouadi K, Sutton JM, et al. Poly(N-isopropylacrylamide-co-allylamine) (PNIPAM-co-ALA) nanospheres for the thermally triggered release of Bacteriophage K. Eur J Pharm Biopharm. 2015;96:437-41.[Crossref] [PubMed] 
  60. Abdulamir AS, Jassim SA, Abu Bakar F. Novel approach of using a cocktail of designed bacteriophages against gut pathogenic E. coli for bacterial load biocontrol. Ann Clin Microbiol Antimicrob. 2014;26;13:39.[Crossref] [PubMed] [PMC] 
  61. Dai M, Senecal A, Nugen SR. Electrospun water-soluble polymer nanofibers for the dehydration and storage of sensitive reagents. Nanotechnology. 2014;6;25(22):225101.[Crossref] [PubMed] 
  62. Salalha W, Kuhn J, Dror Y, Zussman E. Encapsulation of bacteria and viruses in electrospun nanofibres. Nanotechnology. 2006;28;17(18):4675-81.[Crossref] [PubMed] 
  63. Kim S, Jo A, Ahn J. Application of chitosan-alginate microspheres for the sustained release of bacteriophage in simulated gastrointestinal conditions. Int J Food Sci Technol. 2015;50(4):913-8.[Crossref] 
  64. Kaikabo AA, AbdulKarim SM, Abas F. Evaluation of the efficacy of chitosan nanoparticles loaded ΦKAZ14 bacteriophage in the biological control of colibacillosis in chickens. Poult Sci. 2017;1;96(2):295-302.[Crossref] [PubMed] [PMC] 
  65. Tang Z, Huang X, Sabour PM, Chambers JR, Wang Q. Preparation and characterization of dry powder bacteriophage K for intestinal delivery through oral administration. LWT - Food Science and Technology. 2015;60(1):263-70.[Crossref] 
  66. Dini C, Islan GA, Castro GR. Characterization and stability analysis of biopolymeric matrices designed for phage-controlled release. Appl Biochem Biotechnol. 2014;174(6):2031-47.[Crossref] [PubMed] 
  67. Şenel S. Current status and future of chitosan in drug and vaccine delivery. React Funct Polym. 2020;147:104452.[Crossref] 
  68. Vinner GK, Richards K, Leppanen M, Sagona AP, Malik DJ. Microencapsulation of enteric bacteriophages in a ph-responsive solid oral dosage formulation using a scalable membrane emulsification process. Pharmaceutics. 2019;14;11(9):475.[Crossref] [PubMed] [PMC] 
  69. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev. 2012;64:18-23.[Crossref] 
  70. Brown TL, Petrovski S, Dyson ZA, Seviour R, Tucci J. The formulation of bacteriophage in a semi solid preparation for control of propionibacterium acnes growth. PLoS One. 2016;10;11(3):e0151184.[Crossref] [PubMed] [PMC] 
  71. Shakeel F, Ramadan W, Faisal MS, Rizwan M, Faiyazuddin M, Mustafa G, et al. Transdermal and topical delivery of anti-inflammatory agents using nanoemulsion/ microemulsion: an updated review. Curr Nanosci. 2010;6(2):184-98.[Crossref] 
  72. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-60.[Crossref] [PubMed] 
  73. Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 2015;5(2):123-7.[Crossref] [PubMed] [PMC] 
  74. Cinquerrui S, Mancuso F, Vladisavljević GT, Bakker SE, Malik DJ. Nanoencapsulation of bacteriophages in liposomes prepared using microfluidic hydrodynamic flow focusing. Front Microbiol. 2018;12;9:2172.[Crossref] [PubMed] [PMC] 
  75. Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;14;115(19):10938-66.[Crossref] [PubMed] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com